Prometheus Biosciences In... (RXDX)
NASDAQ: RXDX
· Real-Time Price · USD
199.92
0.18 (0.09%)
At close: Jun 15, 2023, 10:00 PM
Prometheus Biosciences Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
Revenue | 4M | 6.81M | 7.19M | 7.23M | 6.29M | 3.13M | 2.56M | 1.91M | 1.76M | 1.23M | 766K |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 4M | 6.81M | 7.19M | 7.23M | 6.29M | 3.13M | 2.56M | 1.91M | 1.76M | 1.23M | 766K |
Operating Income | -162.38M | -145.78M | -134.39M | -122.8M | -107.68M | -87.8M | -66.42M | -47.09M | -34.8M | -29.01M | -20.44M |
Interest Income | 11.82M | 4.03M | 1.49M | 404K | 120K | 108K | 87K | 63K | 29K | 13K | 8K |
Pretax Income | -150.56M | -141.75M | -132.91M | -122.96M | -108.32M | -90.19M | -69.48M | -49.98M | -38.13M | -31.14M | -21.93M |
Net Income | -149.13M | -140.29M | -133.14M | -124.31M | -109.98M | -91.89M | -68.9M | -48.51M | -37.95M | -37.14M | -28.52M |
Selling & General & Admin | 45.02M | 39.72M | 35.09M | 35.07M | 31.37M | 28.5M | 24.81M | 17.73M | 13.92M | 11.09M | 7.37M |
Research & Development | 121.36M | 112.87M | 106.49M | 94.96M | 82.6M | 62.43M | 44.17M | 31.27M | 22.64M | 19.15M | 13.84M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 166.38M | 152.59M | 141.58M | 130.03M | 113.97M | 90.93M | 68.98M | 49M | 36.56M | 30.24M | 21.21M |
Interest Expense | 321K | 351K | -1.37M | -1.36M | -1.49M | -861K | 1.5M | 1.85M | 2.25M | 2.13M | 1.49M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 166.38M | 152.59M | 141.58M | 130.03M | 113.97M | 90.93M | 68.98M | 49M | 36.56M | 30.24M | 21.21M |
Income Tax Expense | -1.87M | -1.67M | 237K | 1.34M | 1.7M | 1.73M | 29K | 33K | -6K | -2K | 6K |
Shares Outstanding (Basic) | 47.46M | 42.95M | 41.22M | 39.24M | 39.01M | 38.92M | 38.85M | 38.81M | 36.71M | 26.98M | 26.98M |
Shares Outstanding (Diluted) | 47.46M | 42.95M | 41.22M | 39.24M | 39.01M | 38.92M | 38.85M | 38.81M | 36.71M | 26.98M | 26.98M |
EPS (Basic) | -3.49 | -3.45 | -3.36 | -3.18 | -2.82 | -2.38 | -1.89 | -1.45 | -1.27 | -1.38 | -1.06 |
EPS (Diluted) | -3.49 | -3.45 | -3.36 | -3.18 | -2.82 | -2.38 | -1.89 | -1.45 | -1.27 | -1.38 | -1.06 |
EBITDA | -160.63M | -143.9M | -134.21M | -124.35M | -109.61M | -90.88M | -67.2M | -46.51M | -35.58M | -34.9M | -26.94M |
EBIT | -159.53M | -142.86M | -135.38M | -124.32M | -109.81M | -91.06M | -67.99M | -48.13M | -35.88M | -29.01M | -20.44M |
Depreciation & Amortization | 2.2M | 2.09M | 180K | -1.02M | -1.45M | -1.52M | 203K | 155K | 126K | 109K | 79K |